A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-07. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Shorter HRTs support the development of non-exoelectrogenous bacteria which can reduce the Coulombic efficiency electrochemical performance of the fuel cell if the anodophiles must compete for resources or if they do not have ample time to effectively degrade nutrients.
Alexei Sayle (born 7 August 1952), English actor, author, stand-up comedian, television presenter and former recording artist; voted the 18th greatest stand-up comic of all time on Channel 4's 100 Greatest Stand-Ups in 2007; In an updated 2010 poll he came 72nd. has written two short story collections, five novels, including a graphic novel and a radio series spin-off book, as well as columns for various publications; has written for Time Out and the Sunday Mirror; was one of eight contributory authors to the BBC Three competition End of Story. Simon Schama (born 13 February 1945), author of Lithuanian Jewish ancestry, specialising in art history, Dutch history, Jewish history, and French history. He is a University Professor of History and Art History at Columbia University, New York. Isaac Schapera FBA FRAI (23 June 1905 Garies, Cape Colony – 26 June 2003 London, England); of South African Jewish-Russian Jewish ancestry; author of numerous highly regarded anthropology books and over 200 monographs and scholarly academic papers on Africa;social anthropologist at London School of Economics specialising in South Africa; notable for his ethnographic and typological studies of the indigenous peoples of Botswana and South Africa; one of the founders of group that would develop British social anthropology, and students included important figures of anthropology, such as Ernest Gellner, Eileen Krige, Hilda Kuper, Max Gluckman, John Comaroff, Johan Frederik Holleman and Jean Comaroff.
== History == In 1938, the Clinical Maternity Hospital No.3 of Yerevan was established. The current building has been operational since 1964. In 2001, the maternity hospital was transformed into the Shengavit Medical Center with a share belonging to the Yerevan municipality. In 2002, the ownership of the hospital became the property of the staff and it was reorganized into a multi-disciplinary clinical-diagnostic institution.
Sources: en.wikipedia.org
Apiin (apigenin 7-O-apioglucoside), isolated from parsley and celery Apigetrin (apigenin 7-glucoside), found in dandelion coffee Vitexin (apigenin 8-C-glucoside) Isovitexin (apigenin 6-C-glucoside) Rhoifolin (apigenin 7-O-neohesperidoside) Schaftoside (apigenin 6-C-glucoside 8-C-arabinoside)
Representative Alexandria Ocasio-Cortez appeared on Bluesky a week after legacy blue checkmarks were removed. After beseeching Musk, actor Charlie Sheen regained his checkmark. Musician Sean Ono Lennon showed confusion towards celebrities who refused to pay for Twitter Blue. Ardent supporters of Musk have defended Twitter Blue, particularly noting its price point. Internet entrepreneur Jason Calacanis, entrepreneur David O. Sacks, and essayist Nassim Nicholas Taleb placed immense value into the subscription while tweeting about it, with Taleb calling those who pay for other products and services monthly but not Twitter Blue "domain dependent misers!" Right-wing Twitter user Catturd called critics of Twitter Blue "elitist snobs".
=== Established lesion === The hallmark of the established lesion is the overwhelming presence of plasma cells in relation to the prior stages of inflammation. Beginning two to three weeks after first plaque formation, the established lesion is widespread in both human and animals populations and can be seen commonly associated with the placement of orthodontic bands on molars. Similar to the initial and early lesions, the established lesion features an inflammatory reaction confined to the area near the base of the gingival sulcus, but unlike prior stages, displays plasma cells clustered around blood vessels and between collagen fibers outside the immediate area of the reaction site. While most of the plasma cells produce IgG, a significant number do produce IgA (and rarely, some produce IgM). The presence of complement and antigen-antibody complexes is evident throughout the connective and epithelial tissue. It is in the established lesion that epithelial proliferation and apical migration begin. In health, the junctional epithelium creates the most coronal attachment of the gum tissue to the tooth at or near the cementoenamel junction. In the established lesion of periodontal disease, the connective tissue lying subjacent to the junctional epithelium is nearly destroyed, failing to properly support the epithelium and buttress it against the tooth surface.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.